← boardnext 2026-09next 2026-12-30
SUPN
Supernus Pharmaceuticals, Inc.distress 0/10 · well-funded / low risk$46.22-2%today-19% from 52w high
Lead: Parkinson's disease motor fluctuations · est. market ~$6B (approx, global)
Revenue
$208M
Liquidity
$647M
Runway
—
Shares 1y
+4%
Price & events
-5.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-4.1%
1W
+3.9%
1M
-8.3%
3M
-4.2%
6M
+40.2%
1Y
+54.6%
2Y
+69.5%
5Y
+83.9%
All
Overview
- Market Cap
- $2.68B
- Volume
- 23.52K
- 52 Week Range
- $32.34 – $57.00
- Total Shares
- 58.04M
- Float Shares
- 52.12M
- Short %
- 15.12%
- % Held by Insiders
- 4.46%
- % Held by Institutions
- 102.88%
- RVOL
- 0.03x
- Beta
- 0.54
Pipeline stages · 2 programs
SPN-817
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BIS-001ER
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-11-15 | Phase 3 | SPN-812 | Attention-Deficit/Hyperactivity Disorder | — | active not recruiting |
| 2026-12-30 Estimated 50% readout ~2027-02-13 | Phase 1/2 | BIS-001ER | Focal Impaired Awareness Seizures | — | active not recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | SPN-821 2400 mg | Major Depressive Disorder (MDD) | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | SPN-817 | Focal Onset Seizures | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 2 | SPN-817 | Focal Onset Seizures | — | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 2 | SPN-817 | Epilepsy, Seizures, Epileptic | — | recruiting |
Catalyst news & presentations · 12
- 2026Guided 40%trial initiationsecondaryPhase 1SPN-443 · Initiate Phase 1 study in healthy volunteersSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- by the end of 2025trial initiationsecondaryPhase 2SPN-820 · Initiate Phase 2b study in MDDSEC 8-K
- second quarter 2025conferencedata presentationsecondaryONAPGO (apomorphine hydrochloride) · Product availabilitySEC 8-K
- first-half 2025readoutPhase 2SPN-820 · Topline results from Phase 2b randomized double-blind placebo-controlled studySEC 8-K
- 2025-06-13partnershipZurzuvae · Agreement to acquire Sage Therapeutics including rights to Zurzuvae through collaboration with Biogen.SEC 8-K
- February 4, 2025conferencedata presentationsecondaryPhase 3ONAPGO (apomorphine hydrochloride) · FDA approval announcedSEC 8-K
- February 1, 2025PDUFAPDUFASPN-830 · User fee goal date for NDA decisionSEC 8-K
- November 2024enrollment completesecondaryPhase 2SPN-820 · Expected to complete enrollment in Phase 2b studySEC 8-K
- October 17, 2024 at 4:30 p.m. ETconferencedata presentationsecondaryPhase 2SPN-820 · Webcast and conference call to review open-label Phase 2a study data.SEC 8-K
- 2024-08-19filing acceptanceFiled (NDA/BLA)SPN-830 · FDA acknowledged resubmission of NDA for apomorphine infusion deviceSEC 8-K
- August 1, 2024regulatory submissionFiled (NDA/BLA)SPN-830 · Resubmitted NDA for SPN-830 apomorphine infusion deviceSEC 8-K
Approved drugs (5)
- QELBREEVILOXAZINE HYDROCHLORIDE2021 · Prescription
- OSMOLEX ERAMANTADINE HYDROCHLORIDE2018 · Discontinued
- GOCOVRIAMANTADINE HYDROCHLORIDE2017 · Prescription
- TROKENDI XRTOPIRAMATE2013 · Prescription
- OXTELLAR XROXCARBAZEPINE2012 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $64 (+37% upside) · 6 analysts
- 2026-07-09Cantor FitzgeraldOverweight
- 2025-12-19StifelHold
- 2025-10-29B of A SecuritiesBuy
- 2025-10-23TD CowenBuy
- 2025-10-09Piper SandlerNeutral → Overweight
- 2025-09-30Cantor FitzgeraldOverweight
Competitors — Parkinson's disease motor fluctuations
- none identified
Recent news
- 2026-07-23Supernus Pharmaceuticals to announce Q2 2026 results on August 4 - scanx.trade
- 2026-07-23Supernus Pharmaceuticals to Announce Q2 2026 Financial Results and Host Investor Conference Call on August 4, 2026 1 – Minichart - Minichart
- 2026-07-22Supernus to Report Q2 2026 Results, Conference Call Scheduled for August 4 - TradingView
- 2026-07-22Supernus CEO and CFO to host Aug. 4 second-quarter webcast - Stock Titan
- 2026-07-22Supernus Pharmaceuticals to Announce Second Quarter 2026 - GlobeNewswire
- 2026-07-22Supernus Pharmaceuticals to Announce Second Quarter 2026 - GlobeNewswire
- 2026-07-21Avoiding Lag: Real-Time Signals in (SUPN) Movement - Stock Traders Daily
- 2026-07-19ETFs Investing in Supernus Pharmaceuticals, Inc. Stocks - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.